**Abstract**

*Objective:* Anxiety disorders have a lifetime prevalence of almost 30% and pose a huge burden on both patient and society. Available treatment options commonly induce adverse effects, urging the need for novel compounds. Neuropeptide S (NPS) has attracted attention due to its anxiolytic properties in rodents. The present study investigated the impact of NPS overexpression on anxiety-related behavior by infusing a recombinant adeno-associated virus (rAAV) into the medial amygdala.

*Methods:* Using stereotaxic surgery, viral vectors (rAAV-NPS vs. rAAV-Empty) were injected bilaterally into the medial amygdala of male adult Wistar rats using a thin glass micropipette. Behavior was characterized using standard anxiety, locomotion and depression tests (Elevated plus maze (EPM), Light/dark box (LDB), Open field (OF), Forced swim test (FST)). Immunohistochemical stainings were performed to verify overexpression of NPS. Statistical significance of differences between treatment groups was assessed using an independent samples t-test.

*Results:* Results showed that the experimental group (rAAV-NPS) spent significantly more time on the open arm in the EPM paradigm compared to the control group (rAAV-Empty), indicating an anxiolytic effect of NPS (*p*=.018). Importantly, this anxiolytic effect could be delineated from locomotion, since no treatment differences across conditions were observed in the OF. Similarly, no confounding effects could be found when measuring body weight or depression-related behavior. Histology revealed NPS-positive cells in the medial amygdala in the experimental but not control group, pointing towards successful transduction.

*Conclusions:* This is the first study successfully demonstrating anxiolytic properties of NPS via transgenic overexpression. Our results are largely consistent with studies elucidating the role of NPS in acute treatments, therefore providing evidence for the validity of both our viral vector and distinct long-lasting mechanisms of NPS. In sum, NPS remains an attractive candidate for novel compounds targeting anxiety pathophysiology.
